Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of Debrisoquine and its Use as a Marker For CYP2D6 Hydroxylation Capacity

23 Dec 2008

Abstract excerpt

Debrisoquine hydroxylation polymorphism is by far the most thoroughly studied genetic polymorphism of the CYP2D6 drug-metabolizing enzyme. Debrisoquine hydroxylation phenotype has been the most used test in humans to evaluate CYP2D6 activity. Two debrisoquine hydroxylation phenotypes have been described: poor and extensive metabolizers. A group with a very low debrisoquine metabolic ratio within the extensive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hormonal and reproductive studies
Share to Pharmacogenetics and Drug Metabolism
Share to Schizophrenia research and treatment

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19102711
DOI: 10.2217/14622416.10.1.17

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of Debrisoquine and its Use as a Marker For CYP2D6 Hydroxylation CapacityPMID 19102711Read ↗

Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents.Semantic proximity Read ↗

Genetically determined adverse drug reactions involving metabolism.Semantic proximity Read ↗

[Debrisoquine hydroxylation test as an example of new possibilities of research in psychopharmacology].Semantic proximity Read ↗

Genetic basis for differences in debrisoquin polymorphism between a Spanish and other white populations.Semantic proximity Read ↗

Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes.Semantic proximity Read ↗

Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.Semantic proximity Read ↗

Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia.Semantic proximity Read ↗

[CYP2D6 gene polymorphism in psychiatric patients resistant to standard pharmacotherapy].Semantic proximity Read ↗

Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.Semantic proximity Read ↗

Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implicationSemantic proximity Read ↗

Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype.Semantic proximity Read ↗

An association study of debrisoquine hydroxylase (CYP2D6) polymorphisms in schizophrenia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.